Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

ObjectiveOf 140 chronic myeloid leukemia patients responding to imatinib with complete cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at ≥0.1% level in a minimum of three subsequent samples (minimal duration, 6 − 9 months). Median follow-up of unchanged BCR-ABL transcript level was 12 months (range, 6 − 64). We tested this group of patient for BCR-ABL mutations to reveal resistance development and to evaluate the risk of disease progression.Materials and MethodsAltogether, 134 samples of peripheral blood of these 32 patients were tested for mutation in BCR-ABL kinase domain.ResultsMutation was detected by direct sequencing in 9 of 32 patients (28%). Loss of complete cytogenetic remission or 1 log rise of BCR-ABL was observed in five of nine patients at a median of 5 months (range, 4−17) since first detection of mutation. One patient with no mutation relapsed 12 months after the start of the BCR-ABL plateau. In 5 of 32 patients without mutation (16%), BCR-ABL level significantly decreased after the first plateau to levels that stayed unchanged for a median of 11 months (range, 7−28).ConclusionWe show here that the BCR-ABL constant levels ≥0.1% (BCR-ABL plateau) in imatinib-responding patients may indicate mutation analysis. This approach highly reduces the number of examinations for mutation in chronic myeloid leukemia responders and may present cost-effective alternative applicable in clinical practice.